GSK Canada signs LOI with pCPA for Blenrep multiple myeloma coverage talks - GSK News | RalliesGSK Canada signs LOI with pCPA for Blenrep multiple myeloma coverage talks
G
GSK• Coverage talks in Canada
- GSK Canada completed price negotiations with the pan-Canadian Pharmaceutical Alliance for Blenrep in relapsed or refractory multiple myeloma.
- Talks resulted in a Letter of Intent, a step toward public drug-plan coverage across Canada.
- Funding agreements still require separate decisions by provincial and territorial plans under their own timelines.
- Blenrep was cleared by Health Canada in July 2025 in two combination regimens, including use as early as first relapse.
•
